TLDR Alopecia from CDK 4/6 inhibitors worsens quality of life in breast cancer patients.
This study investigates the impact of alopecia induced by CDK 4/6 inhibitors on the quality of life in 51 female breast cancer patients in the MENA region. Nearly half of the participants experienced alopecia, with 26% at CTCAE grade I and 23% at grade II. The study found that higher alopecia severity significantly worsened quality of life, particularly in emotional, symptomatic, and functional aspects, as measured by the Hair-Specific Skindex-29 questionnaire. Both the severity of alopecia and the specific CDK4/6 inhibitor used were significant predictors of quality-of-life impairment.
1 citations
,
January 2021 in “Skin appendage disorders” Chemotherapy patients don't all lose their hair due to factors like hair growth rates, age, genetics, and the type of drugs used.
17 citations
,
June 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Scalp cooling is an effective way to prevent hair loss from chemotherapy.
September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
7 citations
,
October 2019 in “Annals of palliative medicine” New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
